Jeito Raises €1 Billion for Biotech Investment Fund

Jeito, a prominent investment firm focused on the life sciences sector, has successfully closed its second fund at an impressive €1 billion. This significant capital raise underscores the sustained investor confidence in biotechnology, a field increasingly viewed as a resilient asset class amidst global economic uncertainties.

The firm's latest fund saw a robust participation rate from its existing limited partners, with a substantial number opting to increase their commitments. Alongside this strong re-up activity, Jeito welcomed approximately twenty new investors, diversifying its LP base. Notably, the roster of new backers includes a greater proportion of North American family offices and institutional investors compared to its predecessor fund.

Adding significant weight to the fund's backing, major pharmaceutical players have reaffirmed their support. Sanofi, a returning investor, has reinvested, and has been joined by two other leading pharmaceutical corporations: Pfizer and Servier. This strategic involvement from industry giants highlights the alignment between venture capital and corporate innovation pipelines in the biotech space.

Rafaèle Tordjman, President and Founder of Jeito, commented on the fund's success, emphasizing its capacity to maintain influence in portfolio companies through subsequent funding rounds and to accelerate the development of their drug pipelines. The firm's strategy centers on providing crucial capital to late-stage venture companies, enabling them to navigate the complex path from development to market.

The inaugural fund, which closed at €534 million in 2021, has already demonstrated its efficacy with three successful exits in 2024, all acquired by pharmaceutical companies. The deployment of the new, larger fund commenced mid-2024 with its first investment. The current portfolio comprises eight companies, representing about one-third of the fund's commitments. Jeito aims to build a diversified portfolio of 15 to 20 companies, focusing on transformative innovations within biotechnology.

The biotechnology sector continues to attract substantial investment, driven by advancements in areas like gene therapy, personalized medicine, and novel drug discovery platforms. Despite broader market volatility, the essential nature of healthcare and the long-term potential of scientific breakthroughs provide a compelling investment thesis. Jeito's substantial fundraise positions it to be a key player in financing the next generation of life-saving therapies, benefiting from both its established relationships and new strategic partnerships.